VIA
Virtus Investment Advisers Portfolio holdings
AUM
$296M
This Quarter Return
-1.68%
1 Year Return
+31.42%
3 Year Return
+126.24%
5 Year Return
–
10 Year Return
–
AUM
$368M
AUM Growth
+$368M
(+188%)
Cap. Flow
+$240M
Cap. Flow
% of AUM
65.16%
Top 10 Holdings %
Top 10 Hldgs %
25.49%
Holding
777
New
414
Increased
42
Reduced
13
Closed
237
Top Buys
| 1 |
Virtus Newfleet ABS/MBS ETF
VABS
|
$32.2M |
| 2 |
Virtus Newfleet Short Duration High Yield Bond ETF
VSHY
|
$24.6M |
| 3 |
Virtus SEIX Senior Loan ETF
SEIX
|
$19M |
| 4 |
SMC
Summit Midstream Corporation
SMC
|
$3.67M |
| 5 |
OCCI
OFS Credit Co
OCCI
|
$2.41M |
Top Sells
| 1 |
ICICI Bank
IBN
|
$3.75M |
| 2 |
Virtus Duff & Phelps Clean Energy ETF
VCLN
|
$2.74M |
| 3 |
Apple
AAPL
|
$2.06M |
| 4 |
Microsoft
MSFT
|
$2.02M |
| 5 |
Primoris Services
PRIM
|
$1.86M |
Sector Composition
| 1 | Financials | 24.48% |
| 2 | Healthcare | 11.95% |
| 3 | Technology | 8.6% |
| 4 | Industrials | 8.02% |
| 5 | Energy | 4.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Acadia Pharmaceuticals
ACAD
$4.34B
| $346K | 0.09% |
20,804
-18,566
| -47% | -$308K |
|
|
BPMC
227
DELISTED
Blueprint Medicines
BPMC
| $343K | 0.09% |
+3,878
| New | +$343K |
|
228
Legend Biotech
LEGN
$6.64B
| $343K | 0.09% |
+10,116
| New | +$343K |
|
229
Rhythm Pharmaceuticals
RYTM
$6.75B
| $341K | 0.09% |
+6,446
| New | +$341K |
|
230
Nuveen Churchill Direct Lending
NCDL
$782M
| $340K | 0.09% |
+20,015
| New | +$340K |
|
231
Ardelyx
ARDX
$1.57B
| $336K | 0.09% |
+68,515
| New | +$336K |
|
232
Ligand Pharmaceuticals
LGND
$3.25B
| $332K | 0.09% |
+3,162
| New | +$332K |
|
233
Theravance Biopharma
TBPH
$692M
| $325K | 0.09% |
+36,379
| New | +$325K |
|
234
Biogen
BIIB
$20.5B
| $316K | 0.09% |
+2,311
| New | +$316K |
|
235
Neurocrine Biosciences
NBIX
$13.5B
| $313K | 0.09% |
2,833
-1,152
| -29% | -$127K |
|
236
Regeneron Pharmaceuticals
REGN
$59.8B
| $308K | 0.08% |
+486
| New | +$308K |
|
237
United Therapeutics
UTHR
$17.7B
| $306K | 0.08% |
+994
| New | +$306K |
|
238
Roivant Sciences
ROIV
$8.6B
| $305K | 0.08% |
+30,219
| New | +$305K |
|
239
Aurinia Pharmaceuticals
AUPH
$1.58B
| $298K | 0.08% |
37,051
-45,777
| -55% | -$368K |
|
240
Ionis Pharmaceuticals
IONS
$9.64B
| $293K | 0.08% |
+9,701
| New | +$293K |
|
241
Amicus Therapeutics
FOLD
$2.42B
| $289K | 0.08% |
35,370
+20,270
| +134% | +$165K |
|
242
Phathom Pharmaceuticals
PHAT
$843M
| $282K | 0.08% |
+44,964
| New | +$282K |
|
243
Ultragenyx Pharmaceutical
RARE
$3.04B
| $277K | 0.08% |
+7,655
| New | +$277K |
|
244
Agios Pharmaceuticals
AGIO
$2.36B
| $276K | 0.07% |
+9,408
| New | +$276K |
|
245
BioNTech
BNTX
$24.1B
| $271K | 0.07% |
+2,976
| New | +$271K |
|
246
CRISPR Therapeutics
CRSP
$4.82B
| $269K | 0.07% |
+7,905
| New | +$269K |
|
247
Xeris Biopharma Holdings
XERS
$1.27B
| $265K | 0.07% |
+48,288
| New | +$265K |
|
248
Novavax
NVAX
$1.2B
| $255K | 0.07% |
+39,805
| New | +$255K |
|
249
Soleno Therapeutics
SLNO
$3.56B
| $253K | 0.07% |
+3,543
| New | +$253K |
|
250
Apellis Pharmaceuticals
APLS
$3.51B
| $240K | 0.07% |
+10,967
| New | +$240K |
|